Literature DB >> 18441471

Infliximab treatment for refractory Kawasaki disease with coronary artery aneurysm.

Taku Oishi1, Mikiya Fujieda, Taisuke Shiraishi, Miki Ono, Kazuo Inoue, Akiyoshi Takahashi, Hideo Ogura, Hiroshi Wakiguchi.   

Abstract

Tumor necrosis factor-alpha (TNF-alpha) is considered to be 1 of the factors that induce vasculitis, including coronary artery aneurysm (CA), in Kawasaki disease (KD), because the blood concentration of TNF-alpha is higher in patients with CA compared with those without. Therefore, an anti-TNF-alphaagent (infliximab) was administered to a 1-month-old girl with refractory KD complicated by CA and subsequently, the CA improved and KD was controlled without complications 20 months after the onset.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18441471     DOI： 10.1253/circj.72.850

Source DB:  PubMed          Journal:  Circ J        ISSN： 1346-9843            Impact factor:   2.993


  14 in total

1.  Infliximab treatment for pediatric refractory Kawasaki disease.

Authors:  Laura L Blaisdell; Jennifer A Hayman; Adrian M Moran
Journal:  Pediatr Cardiol       Date:  2011-07-20       Impact factor: 1.655

2.  Interleukin-1β is crucial for the induction of coronary artery inflammation in a mouse model of Kawasaki disease.

Authors:  Youngho Lee; Danica J Schulte; Kenichi Shimada; Shuang Chen; Timothy R Crother; Norika Chiba; Michael C Fishbein; Thomas J A Lehman; Moshe Arditi
Journal:  Circulation       Date:  2012-02-23       Impact factor: 29.690

Review 3.  Treatment Options for Resistant Kawasaki Disease.

Authors:  Linny Kimly Phuong; Nigel Curtis; Peter Gowdie; Jonathan Akikusa; David Burgner
Journal:  Paediatr Drugs       Date:  2018-02       Impact factor: 3.022

4.  Predicting factors for refractory kawasaki disease.

Authors:  Young-Sun Do; Ki-Won Kim; Jin-Kyong Chun; Byung Ho Cha; Mee Kyung Namgoong; Hae Yong Lee
Journal:  Korean Circ J       Date:  2010-05-27       Impact factor: 3.243

5.  Amino-terminal pro-B-type natriuretic peptide in refractory Kawasaki disease.

Authors:  Fernando Maria de Benedictis; Massimo Colaneri; Patrizia Osimani; Maria Grazia Bettuzzi
Journal:  Pediatr Cardiol       Date:  2009-04-14       Impact factor: 1.655

6.  Clinical use of biologics in vasculitis syndromes.

Authors:  Marino Paroli
Journal:  Biologics       Date:  2012-10-25

Review 7.  Recent understanding on diagnosis and management of central nervous system vasculitis in children.

Authors:  Ludovico Iannetti; Roberta Zito; Simone Bruschi; Laura Papetti; Fiorenza Ulgiati; Francesco Nicita; Francesca Del Balzo; Alberto Spalice
Journal:  Clin Dev Immunol       Date:  2012-09-12

8.  Catastrophic Kawasaki disease unresponsive to IVIG in a 3-month-old infant: a diagnostic and therapeutic challenge.

Authors:  Cristina Medeiros Ribeiro de Magalhães; Natália Ribeiro de Magalhães Alves; Adriana Valença de Melo; Clodoaldo Abreu da Silveira Junior; Yanna Karla de Medeiros Nόbrega; Lenora Gandolfi; Riccardo Pratesi
Journal:  Pediatr Rheumatol Online J       Date:  2012-08-28       Impact factor: 3.054

9.  Infliximab for the treatment of intravenous immunoglobulin resistant Kawasaki disease complicated by coronary artery aneurysms: a case report.

Authors:  Robert J Brogan; Despina Eleftheriou; James Gnanapragasam; Nigel J Klein; Paul A Brogan
Journal:  Pediatr Rheumatol Online J       Date:  2009-01-21       Impact factor: 3.054

Review 10.  Management of Kawasaki disease.

Authors:  D Eleftheriou; M Levin; D Shingadia; R Tulloh; N J Klein; P A Brogan
Journal:  Arch Dis Child       Date:  2013-10-25       Impact factor: 3.791
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.